163 related articles for article (PubMed ID: 26974376)
21. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.
Mishra RK; Shum AK; Platanias LC; Miller RJ; Schiltz GE
Sci Rep; 2016 Jul; 6():30155. PubMed ID: 27456816
[TBL] [Abstract][Full Text] [Related]
22. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
23. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
[TBL] [Abstract][Full Text] [Related]
25. Recent Developments in the Medicinal Chemistry for New Small-Molecule Therapeutics to Treat HIV-AIDS.
Saha M; Bhattacharya S
Curr Top Med Chem; 2019; 19(18):1569-1570. PubMed ID: 31612809
[No Abstract] [Full Text] [Related]
26. Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.
Vinader V; Ahmet DS; Ahmed MS; Patterson LH; Afarinkia K
PLoS One; 2013; 8(10):e78744. PubMed ID: 24205302
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.
Miller JF; Gudmundsson KS; D'Aurora Richardson L; Jenkinson S; Spaltenstein A; Thomson M; Wheelan P
Bioorg Med Chem Lett; 2010 May; 20(10):3026-30. PubMed ID: 20443225
[TBL] [Abstract][Full Text] [Related]
28. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
29. Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj R; Bridger G; McEachern E; Harwig C; Smith C; Kaller A; Veale D; Yee H; Skupinska K; Wauthy R; Wang L; Baird I; Zhu Y; Burrage K; Yang W; Sartori M; Huskens D; De Clercq E; Schols D
Bioorg Med Chem Lett; 2011 Mar; 21(5):1414-8. PubMed ID: 21295470
[TBL] [Abstract][Full Text] [Related]
30. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
[TBL] [Abstract][Full Text] [Related]
31. A targeted covalent small molecule inhibitor of HIV-1 fusion.
Zhou G; He L; Li KH; Pedroso CCS; Gochin M
Chem Commun (Camb); 2021 May; 57(37):4528-4531. PubMed ID: 33956029
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitors of CXCR4.
Debnath B; Xu S; Grande F; Garofalo A; Neamati N
Theranostics; 2013; 3(1):47-75. PubMed ID: 23382786
[TBL] [Abstract][Full Text] [Related]
33. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure.
Tamamura H; Ojida A; Ogawa T; Tsutsumi H; Masuno H; Nakashima H; Yamamoto N; Hamachi I; Fujii N
J Med Chem; 2006 Jun; 49(11):3412-5. PubMed ID: 16722661
[TBL] [Abstract][Full Text] [Related]
34. Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents.
Miller JF; Turner EM; Gudmundsson KS; Jenkinson S; Spaltenstein A; Thomson M; Wheelan P
Bioorg Med Chem Lett; 2010 Apr; 20(7):2125-8. PubMed ID: 20207537
[TBL] [Abstract][Full Text] [Related]
35. Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors.
Puig de la Bellacasa R; Gibert A; Planesas JM; Ros-Blanco L; Batllori X; Badía R; Clotet B; Esté J; Teixidó J; Borrell JI
Org Biomol Chem; 2016 Jan; 14(4):1455-1472. PubMed ID: 26691389
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1.
Catalano JG; Gudmundsson KS; Svolto A; Boggs SD; Miller JF; Spaltenstein A; Thomson M; Wheelan P; Minick DJ; Phelps DP; Jenkinson S
Bioorg Med Chem Lett; 2010 Apr; 20(7):2186-90. PubMed ID: 20194023
[TBL] [Abstract][Full Text] [Related]
37. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
38. Novel dual small-molecule HIV inhibitors: scaffolds and discovery strategies.
Song A; Yu H; Wang C; Zhu X; Liu K; Ma X
Curr Pharm Des; 2015; 21(7):950-62. PubMed ID: 25269561
[TBL] [Abstract][Full Text] [Related]
39. [A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4].
Kanbara K; Fujii N; Nakashima H
Kansenshogaku Zasshi; 2000 Mar; 74(3):237-44. PubMed ID: 10783578
[TBL] [Abstract][Full Text] [Related]
40. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
Li W; Li X; De Clercq E; Zhan P; Liu X
Eur J Med Chem; 2015 Sep; 102():167-79. PubMed ID: 26276432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
